Live Analyst Rating Changes 1641 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Albert Lowe
C-H
Albert Lowe
Craig-Hallum
Wall Street Analyst
★★★★☆
#475
on 13Foresight · ranked by our own returns
33%
Success Rate
-1.2%
Average Return
6 of 18 calls profitable · +2.4% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 33% of Albert Lowe's ratings turned a profit when each position was held for 1 year — averaging -1.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

79 Buy 6 Hold 0 Sell
Albert's Stock Coverage 19 ratings · 2026-06-22
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
IRD
Opus Genetics
 Jun 16, 2026 BUY Strong Buy
+154.5% avg upside
23 analysts
 — ·
SABS
SAB Biotherapeutics
 Jun 16, 2026 BUY Strong Buy
+161.4% avg upside
13 analysts
$6.00
49.93% Upside
 ·
CRDF
Cardiff Oncology
 Jun 04, 2026 HOLD Strong Buy
+732.8% avg upside
18 analysts
$2.00
65.32% Upside
 -21.9%
NGNE
Neurogene
 May 15, 2026 BUY Buy
+55.5% avg upside
23 analysts
$65.00
106.20% Upside
 -7.1%
ACTU
Actuate Therapeutics, Inc.
 May 12, 2026 BUY Strong Buy
+528.0% avg upside
4 analysts
$12.00
479.74% Upside
 -30.1%
CMPX
Compass Therapeutics
 May 06, 2026 BUY Strong Buy
+373.3% avg upside
19 analysts
 — +8.0%
TSE:EPRX
Eupraxia Pharmaceuticals
 May 05, 2026 BUY Strong Buy
+147.8% avg upside
8 analysts
$19.81
118.74% Upside
 ·
SPRB
Spruce Biosciences
 Apr 27, 2026 BUY Strong Buy
+90.7% avg upside
14 analysts
$140.00
167.36% Upside
 -13.8%
RMNI
Rimini Street
 Apr 02, 2026 BUY Strong Buy
+50.2% avg upside
9 analysts
 — +21.9%
PVLA
Palvella Therapeutics
 Mar 19, 2026 BUY Strong Buy
+45.3% avg upside
27 analysts
 — -0.7%
SKYE
Skye Bioscience
 Mar 11, 2026 HOLD Strong Buy
+1354.2% avg upside
9 analysts
 — +12.3%
RZLT
Rezolute
 Feb 17, 2026 HOLD Strong Buy
+122.8% avg upside
13 analysts
$4.00
20.35% Downside
 -8.0%
ATOS
Atossa Therapeutics
 Feb 12, 2026 BUY Strong Buy
+870.1% avg upside
6 analysts
$10.00
397.53% Upside
 +13.5%
ELDN
Eledon Pharmaceuticals
 Jan 23, 2026 BUY Strong Buy
+302.0% avg upside
10 analysts
 — +77.6%
MDWD
Mediwound
 Jan 12, 2026 BUY Strong Buy
+51.7% avg upside
13 analysts
 — -17.3%
LCTX
Lineage Therap
 Nov 25, 2025 BUY Strong Buy
+342.8% avg upside
16 analysts
$3.00
147.94% Upside
 -30.5%
PMVP
PMV Pharmaceuticals
 Nov 13, 2025 BUY Strong Buy
+1200.9% avg upside
12 analysts
$4.00
254.03% Upside
 -5.1%
PHAT
Phathom Pharmaceuticals
 Jun 06, 2024 BUY Strong Buy
+163.8% avg upside
14 analysts
 — -7.8%
COHR
Coherent Corp
 Jun 04, 2024 BUY Strong Buy
-35.5% avg upside
33 analysts
$14.00
96.31% Downside
 +23.9%
🔒 14 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Albert Lowe — Frequently Asked Questions
How accurate are Albert Lowe's stock ratings?
Based on the calls 13Foresight could measure, about 33% of Albert's ratings were profitable over a one-year hold, with an average return of -1.2% per rating, or +2.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Albert ranked on 13Foresight?
Albert Lowe is currently ranked #475 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Albert cover?
Albert most recently has ratings on IRD, SABS, CRDF, NGNE, ACTU, CMPX, TSE:EPRX, SPRB, RMNI, PVLA, SKYE, RZLT and 7 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.